Akari Therapeutics, Plc
AKTX
$1.10
-$0.095-7.98%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.71M | 2.24M | 3.71M | 2.70M | 2.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.85M | 5.56M | 5.99M | 3.80M | 2.51M |
| Operating Income | -1.85M | -5.56M | -5.99M | -3.80M | -2.51M |
| Income Before Tax | -2.90M | -7.56M | -5.57M | -3.50M | -2.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.90M | -7.56M | -5.57M | -3.50M | -2.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.90M | -7.56M | -5.57M | -3.50M | -2.87M |
| EBIT | -1.85M | -5.56M | -5.99M | -3.80M | -2.51M |
| EBITDA | -1.85M | -5.56M | -5.98M | -3.80M | -2.51M |
| EPS Basic | -474.80 | -1.61K | -1.66K | -1.30K | -1.14K |
| Normalized Basic EPS | -0.09 | -0.38 | -0.52 | -0.41 | -0.35 |
| EPS Diluted | -474.80 | -1.61K | -1.66K | -1.30K | -1.14K |
| Normalized Diluted EPS | -0.09 | -0.38 | -0.52 | -0.41 | -0.35 |
| Average Basic Shares Outstanding | 12.19M | 9.42M | 6.73M | 5.40M | 5.06M |
| Average Diluted Shares Outstanding | 6.00K | 4.70K | 3.30K | 2.60K | 2.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
